Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency

Clinical Cancer Research

Volumn 7, Issue 5, 2001, Pages 1149-1153

  Van Kuilenburg, André B P ^a   Muller, Erik W ^b   Haasjes, Janet ^a   Meinsma, Rutger ^a   Zoetekouw, Lida ^a   Waterham, Hans R ^a   Baas, Frank ^a   Richel, Dick J ^a   Van Gennip, Albert H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SLINGELAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; CANCER PATIENT; CAUCASIAN; CONTROLLED STUDY; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEFICIENCY; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; HOMOZYGOSITY; HUMAN; HUMAN CELL; LETHALITY; LEUKOPENIA; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); EXONS; FATAL OUTCOME; FEMALE; FIBROBLASTS; FLUOROURACIL; GENE FREQUENCY; HUMANS; LEUKOCYTES, MONONUCLEAR; MUTATION; OXIDOREDUCTASES; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; THYMINE; URACIL;

EID: 0034901306     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Efficacy of intravenous continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal cancer
2. High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during prolonged drug infusion
3. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
4. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer- Status of the art
5. Clinical pharmacokinetics of 5-fluorouracil and its metabolism in plasma, urine, and bile
6. Population study of dihydropyrimidine dehydrogenase in cancer patients
7. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy
8. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
9. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity
10. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity
11. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity
12. Known variant DPYD alleles do not explain DPD deficiency in cancer patients
13. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency
14. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
15. Dihydropyrimidine dehydrogenase pharmacogenetics in Caucasian subjects
16. Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation
17. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency
18. Measurement of protein using bicinchoninic acid
19. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency
20. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice
21. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase
22. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
23. 5-Ethynyluracil (776C85): Inactivation of dihydropyrimidine dehydrogenase in vivo
24. Characterization of the human dihydropyrimidine dehydrogenase gene
25. Common DPYD mutation associated with 5-fluorouracil toxicity detected by PCR-mediated site-directed mutagenesis